Loading
A phase 2 trial of COVID-19 Vaccine in non-Hodgkin lymphoma and multiple myeloma, run by GeoVax, Inc., active and no longer recruiting.
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer is a phase 2 interventional study registered as NCT04977024 by GeoVax, Inc., with 63 participants enrolled, started 2021-09-27 and due to reach its primary completion in 2026-12-31. Interventions recorded: COVID-19 Vaccine and Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Multiple myeloma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Multiple myeloma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Multiple myeloma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/